SpringWorks Therapeutics stock (US86960K1088): Merck acquisition costs impact Q1 results

Merck KGaA reported Q1 2026 EBITDA pre down 9.7% due to FX effects and SpringWorks Therapeutics acquisition costs, per company release on May 13.

SpringWorks Therapeutics (US86960K1088), a precision oncology company, features in Merck KGaA's Q1 2026 results released on May 13, 2026. The German pharma giant noted EBITDA pre declined 9.7% year-on-year, attributing it mainly to foreign exchange effects of -8.5% and follow-on costs from the SpringWorks acquisition, according to Merck Group as of 05/13/2026. SpringWorks, known for tumor-selective cancer medicines, was acquired in a cash merger where shareholders received $47 per share, as documented in corporate action records.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: SpringWorks Therapeutics, Inc.
• Sector/industry: Biotechnology / Precision Oncology
• Headquarters/country: United States
• Core markets: US, global oncology
• Key revenue drivers: Cancer therapies like nirogacestat
• Home exchange/listing venue: Nasdaq (SWTX)
• Trading currency: USD

SpringWorks Therapeutics: core business model

SpringWorks Therapeutics focused on developing and commercializing medicines for rare cancers and pediatric solid tumors. Its lead product, nirogacestat, an oral gamma secretase inhibitor, received FDA approval for desmoid tumors in 2023. The company targeted genetically defined cancers with high unmet needs, according to its investor relations site as of 05/14/2026.

Prior to acquisition, SpringWorks operated as a clinical-stage biotech with a pipeline emphasizing precision oncology. The business model relied on partnerships and internal development to advance therapies through late-stage trials and commercialization.

Main revenue and product drivers for SpringWorks Therapeutics

Key revenue came from nirogacestat sales post-approval, targeting desmoid tumor patients. The drug addressed a rare condition with limited treatments. Pipeline candidates included mirdametinib for neurofibromatosis type 1-associated plexiform neurofibromas, per company disclosures.

Acquisition by Merck KGaA integrated these assets into a larger portfolio, potentially accelerating global development. Follow-on costs noted in Merck's Q1 impacted EBITDA, highlighting integration expenses as of Q1 2026 reporting period published 05/13/2026.

Industry trends and competitive position

The precision oncology sector grows with advances in genetic profiling and targeted therapies. SpringWorks competed with firms like Allogene Therapeutics in cell therapy spaces, though focused on small molecules. US investors track such biotechs for innovation exposure amid rising cancer incidence.

Why SpringWorks Therapeutics matters for US investors

Listed on Nasdaq as SWTX, SpringWorks offered US investors access to rare cancer treatments with FDA-validated pathways. Post-acquisition, it underscores M&A trends in biotech, where larger pharmas like Merck acquire innovative assets to bolster pipelines relevant to the US healthcare market.

Conclusion

SpringWorks Therapeutics' integration into Merck KGaA highlights ongoing consolidation in biotech, with Q1 2026 costs reflecting acquisition realities. US investors monitor such deals for portfolio impacts on Nasdaq-listed names. Developments continue to shape oncology innovation.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.